528 related articles for article (PubMed ID: 17630405)
1. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.
Carter CS; Barch DM
Schizophr Bull; 2007 Sep; 33(5):1131-7. PubMed ID: 17630405
[TBL] [Abstract][Full Text] [Related]
2. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
[TBL] [Abstract][Full Text] [Related]
3. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
Buchanan RW
Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
[No Abstract] [Full Text] [Related]
4. Executive functioning component mechanisms and schizophrenia.
Kerns JG; Nuechterlein KH; Braver TS; Barch DM
Biol Psychiatry; 2008 Jul; 64(1):26-33. PubMed ID: 18549874
[TBL] [Abstract][Full Text] [Related]
5. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.
Carter CS; Barch DM; Buchanan RW; Bullmore E; Krystal JH; Cohen J; Geyer M; Green M; Nuechterlein KH; Robbins T; Silverstein S; Smith EE; Strauss M; Wykes T; Heinssen R
Biol Psychiatry; 2008 Jul; 64(1):4-10. PubMed ID: 18466880
[TBL] [Abstract][Full Text] [Related]
6. Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models.
Moore H; Geyer MA; Carter CS; Barch DM
Neurosci Biobehav Rev; 2013 Nov; 37(9 Pt B):2087-91. PubMed ID: 24090823
[TBL] [Abstract][Full Text] [Related]
7. The effects of clozapine on cognitive functioning in schizophrenia.
McGurk SR
J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
[TBL] [Abstract][Full Text] [Related]
8. Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative.
Barch DM; Carter CS;
Schizophr Bull; 2008 Jul; 34(4):613-8. PubMed ID: 18499705
[TBL] [Abstract][Full Text] [Related]
9. Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia.
Carter CS
Schizophr Bull; 2005 Oct; 31(4):810-5. PubMed ID: 16107584
[TBL] [Abstract][Full Text] [Related]
10. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Heinrichs RW
Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
[No Abstract] [Full Text] [Related]
11. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
[TBL] [Abstract][Full Text] [Related]
12. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
Harvey PD; Keefe RS
Am J Psychiatry; 2001 Feb; 158(2):176-84. PubMed ID: 11156796
[TBL] [Abstract][Full Text] [Related]
13. The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia.
Barch DM; Smith E
Biol Psychiatry; 2008 Jul; 64(1):11-7. PubMed ID: 18400207
[TBL] [Abstract][Full Text] [Related]
14. Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
Weiss E; Kemmler G; Fleischhacker WW
Arch Gen Psychiatry; 2002 Jun; 59(6):572-3; author reply 573-5. PubMed ID: 12044210
[No Abstract] [Full Text] [Related]
15. The NEWMEDS rodent touchscreen test battery for cognition relevant to schizophrenia.
Hvoslef-Eide M; Mar AC; Nilsson SR; Alsiö J; Heath CJ; Saksida LM; Robbins TW; Bussey TJ
Psychopharmacology (Berl); 2015 Nov; 232(21-22):3853-72. PubMed ID: 26202612
[TBL] [Abstract][Full Text] [Related]
16. Visual perception and its impairment in schizophrenia.
Butler PD; Silverstein SM; Dakin SC
Biol Psychiatry; 2008 Jul; 64(1):40-7. PubMed ID: 18549875
[TBL] [Abstract][Full Text] [Related]
17. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
18. Cognitive effects of conventional and atypical antipsychotics in schizophrenia.
Sharma T
Br J Psychiatry Suppl; 1999; (38):44-51. PubMed ID: 10884899
[No Abstract] [Full Text] [Related]
19. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions.
Green MF
Am J Psychiatry; 2007 Jul; 164(7):992-4. PubMed ID: 17606645
[No Abstract] [Full Text] [Related]
20. Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.
Young JW; Geyer MA
J Psychopharmacol; 2015 Feb; 29(2):178-96. PubMed ID: 25516372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
